Brought to you by 
End of Baxter's rights to Cerus pathogen inactivation system
27 Feb 2006
Executive Summary
For upfront fees, milestones, and an equity investment, Baxter will develop with and license exclusive worldwide rights to Cerus Corp.'s platelet pathogen inactivation systems.
Deal Industry
- Medical Devices
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
End of Baxter's rights to Cerus pathogen inactivation system
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice